Business context and reporting period
GSI Group Inc. (the registrant named in the filing) designs and sells photonics, medical technology and precision motion products, primarily to OEMs. This unaudited Form 10-Q covers the three months ended April 3, 2015; comparisons are with the three months ended March 28, 2014. The filing is for GSI Group Inc., not Novanta Inc.; investors should verify the entity and any successor-company relationship.
Key financial metrics
Amounts are in U.S. dollars. Financial statement amounts are converted from thousands to millions where applicable.
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Sales | $94.6 million | $79.1 million |
| Gross profit / margin | $40.0 million / 42.3% | $32.1 million / 40.6% |
| Operating income from continuing operations | $5.4 million | $4.1 million |
| Income from continuing operations | $3.4 million | $2.9 million |
| Net income attributable to GSI Group Inc. | $3.4 million | $1.0 million |
| Diluted EPS from continuing operations | $0.10 | $0.08 |
| Cash from continuing operating activities | $6.0 million | $2.8 million |
Cash and cash equivalents were $47.5 million at April 3, 2015, down from $51.1 million at year-end 2014. Debt totaled $123.1 million ($33.1 million term loan and $90.0 million revolver), versus $115.0 million at year-end; approximate net debt was $75.6 million. The $175 million revolving facility had $85 million unused and available. The company reported compliance with its covenants: leverage ratio 2.10 versus a 3.00 maximum, and fixed-charge coverage 3.75 versus a 1.50 minimum. Current assets were $193.0 million and current liabilities $60.4 million.
Material changes versus prior comparable period
- Sales rose 19.6%; management attributed 16.2 percentage points to acquisitions and a 5.5 percentage-point adverse effect to foreign exchange, yielding reported organic growth of 8.9%.
- Gross margin increased 1.7 percentage points, and operating income rose 32.7%. Diluted continuing-operations EPS increased from $0.08 to $0.10.
- Segment sales: Laser Products $45.0 million, up 7.4%; Medical Technologies $31.1 million, up 39.1%; Precision Motion $18.5 million, up 24.4%. Medical growth included $10.7 million from JADAK, partly offset by weaker visualization sales. Precision Motion benefited from Applimotion and higher encoder volumes.
- Research and development expense rose to $8.2 million from $5.9 million, reflecting JADAK and increased product investment. Restructuring, acquisition and divestiture costs increased to $2.4 million from $0.8 million.
- Q1 2014 included a $1.9 million after-tax loss from discontinued operations; Q1 2015 had none. The prior-period loss included a write-down of the Scientific Lasers business.
- Foreign-currency translation losses of $4.5 million contributed to a $0.3 million comprehensive loss in Q1 2015, despite net income.
Outlook, commentary, risks and unusual items
- Management said operating cash flows were expected to fund operating and capital needs for at least the next 12 months, with revolver availability as additional liquidity. No numerical earnings or revenue guidance was provided.
- Applimotion was acquired February 19 for a stated purchase price of approximately $14.8 million, including contingent consideration tied to 2015–2017 revenue targets (undiscounted range: zero to $4.0 million). Purchase accounting remained preliminary.
- After quarter-end, on April 15, the company completed the sale of JK Lasers for approximately $31.4 million cash, subject to working-capital adjustments. Management expected a pretax gain of approximately $17–$20 million. JK Lasers generated about $22 million of 2014 sales; the divestiture was not classified as discontinued operations.
- A 2015 restructuring program began to eliminate redundant costs and realign operations; $1.3 million of severance expense was recorded in the quarter. Management said savings were principally intended for reinvestment in higher-growth businesses and lower-cost regions.
- Key risks cited include cyclical OEM/customer capital spending, economic conditions, customer order timing, foreign exchange and interest rates, acquisition integration and divestiture execution, product innovation and supply disruptions, and significant indebtedness. Ordinary-course legal claims were disclosed; management did not expect a material adverse effect but gave no assurance.
- Management reported effective disclosure controls as of April 3, 2015 and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing’s registrant identity: the supplied filing is for GSI Group Inc., whereas the request names Novanta Inc.
- Assess how much reported growth and future performance depend on acquisitions, foreign exchange, and the lower visualization-solutions sales trend.
- Track the final Applimotion purchase-price allocation and contingent consideration, and the realized proceeds, working-capital adjustments and gain on the JK Lasers sale.
- Monitor debt, revolver capacity and covenant headroom, along with cash conversion: receivable days rose to 56 from 53 at year-end and inventory turnover declined to 3.2 from 3.3.
- Evaluate whether restructuring savings offset its costs and whether planned reinvestment supports profitable growth; the filing provides no quantified savings target.